Status:

RECRUITING

Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4

Lead Sponsor:

University of Michigan

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Anxiety

Social Anxiety Disorder

Eligibility:

All Genders

18-24 years

Phase:

NA

Brief Summary

This study seeks to understand emotion regulation in those with young adults with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control...

Eligibility Criteria

Inclusion

  • Primary diagnosis (primary source of distress and/or interference) of generalized anxiety disorder, social anxiety disorder, panic disorder or illness anxiety disorder based on structured interview. Comorbid phobic disorders allowed, but these cannot be the primary source of interference or distress due to the lowered chances of encountering anxiety-provoking stimuli during the study period
  • Score of 2 or more on at least 1 question from GAD/CROSS-AD composite
  • Medically and physically able to consent
  • Not regularly taking any medication, prescription or non-prescription, with psychotropic effects other than:
  • Buspirone, or antidepressant (e.g., selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)) with stable dosage for past 4 weeks
  • The same oral hormonal contraceptive for at least 3 months
  • For females, not currently pregnant or actively trying to become pregnant
  • Ability to tolerate small, enclosed spaces without anxiety
  • No metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition (per protocol)
  • Size compatible with scanner gantry (per protocol)

Exclusion

  • Current diagnosis of Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, or Bipolar Disorder
  • Current substance abuse or dependence (past 6 months)
  • Active suicidality with plan or intent
  • Current psychosis
  • History of serious neurological illness or current medical condition that could compromise brain function, such as liver failure
  • History of closed head injury, e.g., loss of consciousness greater (\>) approximately (\~) 5 minutes, hospitalization, neurological sequela

Key Trial Info

Start Date :

January 9 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2029

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT06563310

Start Date

January 9 2025

End Date

May 1 2029

Last Update

June 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Michigan

Ann Arbor, Michigan, United States, 48109